The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 April 2026•

1 min read

Oncolytics Biotech to Meet FDA for Anal Cancer Treatment Pathway

Key Facts

1Oncolytics Biotech scheduled a Type C meeting with the U.S. FDA for April 16, 2026.

2The meeting will discuss a potential registrational pathway via a single-arm pivotal study for pelareorep in anal cancer.

3The treatment targets patients undergoing second-line and later therapy for squamous cell anal carcinoma (SCAC).

Oncolytics Biotech Inc. (Nasdaq: ONCY) has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for April 16, 2026. The primary objective of the meeting is to discuss a potential registrational pathway for its immunotherapy drug, pelareorep. The company seeks agreement on a streamlined, single-arm pivotal study design for treating squamous cell anal carcinoma (SCAC). This treatment specifically targets patients in the second-line or later stages of the disease. A single-arm study could significantly accelerate the development and approval process compared to traditional randomized trials. Investors view this regulatory progress as a positive step toward commercialization for the clinical-stage biotech firm.

Create Free Account